Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2017
At a glance
- Drugs HBAI 20 (Primary) ; Hepatitis B vaccine recombinant (HBvaxPro)
- Indications Hepatitis B
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 13 Sep 2016 Status changed from active, no longer recruiting to completed.
- 29 Apr 2016 According to a CyTuVax media release, all subjects have been vaccinated twice and the data from this trial will be published in the third quarter of 2016.